News Story: Full Text
Sponsored By
Genentech Biooncology
Please Click On The Above Banner For More Details
Braintumor Website

 

China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma

Al's Comment:

 Optune is finally available in China - 6 years after we had it here in the USA!

In China there are about 45,000 patients diagnosed per year with glioblastoma.  That is more than double the number here in the USA.

The press release states: A large, global phase 3 pivotal clinical study in newly diagnosed glioblastoma showed adding Optune to chemotherapy more than doubled the five-year overall survival rate1

 


Posted on: 05/13/2020

China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma


 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740